コンテンツへスキップ
Merck

Lamotrigine in epilepsy, pregnancy and psychiatry--a drug for all seasons?

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2012-10-06)
Frank J E Vajda, Seetal Dodd, David Horgan
要旨

Lamotrigine has been demonstrated to be effective as both an antiepileptic drug and a mood stabiliser. For epilepsy it is less efficacious than valproate in primary generalised epilepsy, but it is comparable to some traditional drugs in partial epilepsy. In psychiatry it has significant advantages over other mood stabilisers for the treatment and prevention of depressive phases of bipolar illness, but not for the treatment of mania. It has a more benign adverse effect profile than older antiepileptic agents and is not a proven teratogen. Risk of adverse reactions is reduced by commencing treatment at a markedly reduced dose that is gradually increased.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ラモトリジン, ≥98%, powder
Supelco
ラモトリギン 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
USP
ラモトリジン, United States Pharmacopeia (USP) Reference Standard
Supelco
ラモトリジン, Pharmaceutical Secondary Standard; Certified Reference Material
ラモトリジン, European Pharmacopoeia (EP) Reference Standard
システム適合性用ラモトリジン, European Pharmacopoeia (EP) Reference Standard
ラモトリジン, European Pharmacopoeia (EP) Reference Standard